Journal of General Internal Medicine

, Volume 10, Issue 6, pp 351–352 | Cite as

Thrombolytic therapy

Just do it
  • A. Mark Fendrick
Editorials

References

  1. 1.
    Ayanian JZ, Hauptman PJ, Gaudagnoli E, Antman EM, Pashos CL, McNeil BJ. Knowledge and practices of generalist and specialist physicians regarding drug therapy for acute myocardial infarction. N Engl J Med. 1994;331:1136–42.PubMedCrossRefGoogle Scholar
  2. 2.
    Lau J, Antman, EM, Jiminez-Silva J, Kupelnick B, Mosteller F, Chalmers TC. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med. 1992;327:248–54.PubMedCrossRefGoogle Scholar
  3. 3.
    Doorey AJ, Michelson EJ, Topol EJ. Thrombolytic therapy of acute myocardial infarction: keeping the unfulfilled promises. JAMA. 1992;268:3108–14.PubMedCrossRefGoogle Scholar
  4. 4.
    Fendrick AM, Ridker PM, Bloom BS. Improved health benefits of increased and expanded utilization of thrombolytic therapy. Arch Intern Med. 1994;1954:1605–9.CrossRefGoogle Scholar
  5. 5.
    Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico. GISSI-2: A factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65–71.Google Scholar
  6. 6.
    The International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomised between alteplase and streptokinase with or without heparin. Lancet. 1990;336:71–5.CrossRefGoogle Scholar
  7. 7.
    ISIS-3 (Third) International Study of Infarct Survival Collaborative Group. A randomised comparison of streptokinase vs. tissue plasminogen activator vs. anistreplase and of aspirin plus heparin vs. aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753–70.CrossRefGoogle Scholar
  8. 8.
    Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO) Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–82.CrossRefGoogle Scholar
  9. 9.
    Lee KL, Califf RM, Simes J, Van de Werf F, Topol EJ. Holding GUSTO up to the light. Ann Intern Med. 1994;120:876–81.PubMedGoogle Scholar
  10. 10.
    Ridker PM, O’Donnell C, Marder VJ, Hennekens, CH. A response to “Holding GUSTO up to the light.” Ann Intern Med. 1994;120:882–5.Google Scholar
  11. 11.
    Califf RM, Topol EJ, Van de Werf F, Lee KL, Woodlief L. One year followup from the GUSTO I Trial [abstract]. Circulation. 1994;90(4 part 2):I-325.Google Scholar
  12. 12.
    Kalish SC, Gurwitz JH, Krumholz HM, Avorn J. A cost-effectiveness model of thrombolytic therapy for acute myocardial infarction. J Gen Intern Med. 1995;10:321–30.PubMedGoogle Scholar

Copyright information

© Society of General Internal Medicine 1995

Authors and Affiliations

  • A. Mark Fendrick
    • 1
  1. 1.Department of Internal MedicineUniversity of Michigan Medical CenterAnn Arbor

Personalised recommendations